{"id":70674,"date":"2026-05-12T09:08:38","date_gmt":"2026-05-12T09:08:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70674"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"tirzepatide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/tirzepatide\/","title":{"rendered":"Tirzepatida"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es el Tirzepatide?<\/h3>\n<p style=\"margin: 0;\"><strong>Tirzepatida<\/strong> is a 39-amino-acid dual GLP-1 and GIP receptor co-agonist peptide and the active studies molecule behind Mounjaro and Zepbound. It produces the largest body-weight and glycaemic effect of any single peptide in current published studies, with the dual-receptor profile delivering a meaningfully greater response than single GLP-1 agonists in head-to-head trials such as SURPASS-2. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly dosing. Supplied in 5\u00a0mg to 120\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2023788-19-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">4813.45 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS (39 aa, estructura base basada en GIP con Aib<sup>2<\/sup>, Aib<sup>13<\/sup>, and Lys<sup>20<\/sup>-C20 \u00e1cido di\u00e1cido graso acilaci\u00f3n v\u00eda espaciador \u03b3Glu-\u03b3Glu)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para periodos de uso m\u00e1s cortos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es el Tirzepatide?<\/h2>\n<p><strong>Tirzepatida<\/strong> is a 39-amino-acid dual incretin receptor co-agonist that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors with comparable potency. Developed by Eli Lilly and disclosed in 2018, it was the first dual-incretin agonist to reach regulatory approval (Mounjaro for type 2 diabetes in 2022, Zepbound for chronic weight management in 2023). Tirzepatide is built on the GIP peptide backbone \u2014 not the GLP-1 backbone used by semaglutide \u2014 with two \u03b1-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 that resist DPP-4 cleavage and a C20 fatty diacid attached at lysine 20 via two \u03b3-glutamic acid spacers. The C20 acyl chain is one carbon longer than semaglutide&#8217;s C18, producing tighter albumin binding and a slightly different pharmacokinetic profile. Tirzepatide&#8217;s well-characterised structure has empirical formula C<sub>225<\/sub>H<sub>348<\/sub>N<sub>48<\/sub>O<sub>68<\/sub> with average molecular weight 4813.45 Da. Plasma half-life is approximately 120 hours (~5 days), enabling once-weekly subcutaneous dosing in published studies. The compound is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For broader incretin studies, see our <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> y <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> p\u00e1ginas de productos. <\/p>\n<h2>Mecanismo de Acci\u00f3n \u2014 Co-Agonismo Dual de los Receptores GLP-1\/GIP<\/h2>\n<p>Lo que diferencia al tirzepatide de los p\u00e9ptidos de incretina \u00fanica anteriores es su <strong>co-activaci\u00f3n equilibrada de dos receptores distintos<\/strong>, each contributing complementary metabolic effects observed in published studies:<\/p>\n<ul>\n<li><strong>Activaci\u00f3n del receptor de GLP-1 \u2014 saciedad, secreci\u00f3n de insulina en las c\u00e9lulas \u03b2, vaciado g\u00e1strico<\/strong> \u2014 Tirzepatide se une al receptor GLP-1 con una afinidad comparable al GLP-1 nativo, activando la adenilil ciclasa acoplada a G\u03b1<sub>s<\/sub>y la se\u00f1alizaci\u00f3n descendente de cAMP\/PKA. Esto produce los efectos can\u00f3nicos de GLP-1: potenciaci\u00f3n dependiente de glucosa de la secreci\u00f3n de insulina de las c\u00e9lulas \u03b2 pancre\u00e1ticas, supresi\u00f3n del glucag\u00f3n de las c\u00e9lulas \u03b1, retraso del vaciado g\u00e1strico y efectos supresores del apetito central a trav\u00e9s de las neuronas POMC del n\u00facleo arqueado. Este aspecto se superpone con el mecanismo del semaglutide.<\/li>\n<li><strong>Activaci\u00f3n del receptor GIP \u2014 lip\u00f3lisis en adipocitos, gasto energ\u00e9tico, soporte de c\u00e9lulas \u03b2<\/strong> \u2014 The GIP component is what makes tirzepatide pharmacologically distinct. GIP receptor activation enhances insulin secretion in a glucose-dependent manner (complementary to GLP-1&#8217;s effect), but also acts on adipocytes to promote lipolysis under fasting conditions while supporting triglyceride storage in the fed state. Studies suggests GIP-receptor signaling also raises resting energy expenditure modestly and acts in CNS regions distinct from GLP-1, including the dorsomedial hypothalamus. The net effect is an additive body-weight signal beyond what GLP-1 alone produces.<\/li>\n<li><strong>Equilibrio de receptores y ajuste estructural fino<\/strong> \u2014 In radioligand-binding assays, tirzepatide shows higher affinity for the GIP receptor than for the GLP-1 receptor \u2014 an unusual ratio that distinguishes it from earlier dual-agonist candidates. The asymmetry is intentional: the GIP backbone allows higher GIP-receptor potency while the engineered modifications preserve sufficient GLP-1 activity. Tirzepatide is sometimes described as &#8220;GIP-biased&#8221; in receptor pharmacology, which has implications for the differential signalling observed in study models.<\/li>\n<\/ul>\n<p>The C20 fatty diacid acyl tether at lysine 20 binds reversibly to circulating serum albumin, forming a peptide depot that protects tirzepatide from renal clearance and produces the ~120-hour plasma half-life. The double Aib substitution (positions 2 and 13) prevents DPP-4 cleavage at two distinct sites, providing redundant proteolytic protection. Together these structural features convert what would otherwise be a short-acting incretin into a once-weekly peptide. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Tirzepatide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Control gluc\u00e9mico y sensibilidad a la insulina<\/strong> \u2014 comparaci\u00f3n directa con semaglutida y otros monoagonistas de GLP-1 (Frias et al., NEJM 2021 SURPASS-2); modelos de roedores db\/db, ZDF y dieta alta en grasas; efectos sobre sustitutos de HbA1c, glucosa en ayunas y par\u00e1metros del clamp hiperinsulin\u00e9mico-eugluc\u00e9mico<\/li>\n<li><strong>Body weight and adiposity studies<\/strong> \u2014 the SURMOUNT-1 trial showed ~22% body weight reduction at 15\u00a0mg weekly over 72 weeks, the largest single-peptide effect documented in clinical studies at the time; rodent DIO models, body composition (DEXA \/ MRI), respiratory exchange ratio<\/li>\n<li><strong>MASLD\/MASH (enfermedad hep\u00e1tica asociada a disfunci\u00f3n metab\u00f3lica)<\/strong> \u2014 contenido de triglic\u00e9ridos hep\u00e1ticos, ALT\/AST, estadificaci\u00f3n de fibrosis; conjunto de datos del ensayo SYNERGY-NASH<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 efectos sobre la presi\u00f3n arterial, perfiles lip\u00eddicos, progresi\u00f3n de la aterosclerosis en modelos ApoE<sup>-\/-<\/sup> modelos; datos de resultados cardiovasculares SURPASS-CVOT<\/li>\n<li><strong>Sleep apnoea studies<\/strong> \u2014 gravedad de la apnea obstructiva del sue\u00f1o, \u00edndice de apnea-hipopnea en el conjunto de datos SURMOUNT-OSA<\/li>\n<li><strong>Protecci\u00f3n renal en modelos de nefropat\u00eda diab\u00e9tica<\/strong> \u2014 albuminuria, tasa de filtraci\u00f3n glomerular, expansi\u00f3n mesangial en enfermedad renal diab\u00e9tica inducida por estreptozotocina y en ratones Akita<\/li>\n<li><strong>Comparative incretin peptide studies<\/strong> \u2014 referencia para comparaciones de agonista dual vs agonista simple vs agonista triple. Consulte nuestra <a href=\"https:\/\/medsbase.com\/es\/retatrutide-vs-tirzepatide\/\">Gu\u00eda de Retatrutida vs Tirzepatida<\/a> y el <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> p\u00e1gina del producto para comparadores hermanos.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre d\u00f3nde encaja tirzepatida en el panorama de los p\u00e9ptidos metab\u00f3licos, consulte <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> (agonista triple de GLP-1\/GIP\/glucag\u00f3n, el comparador de pr\u00f3xima generaci\u00f3n) y <a href=\"https:\/\/medsbase.com\/es\/ozempic-vs-mounjaro\/\">nuestra gu\u00eda de Ozempic vs Mounjaro<\/a>. Explore el <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks Tirzepatide in eleven lyophilized vial strengths covering the full dose-titration range from pilot dosing through multi-month bulk protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dosis piloto, titulaci\u00f3n de nivel bajo, ciclos cortos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maintenance strength, mid-titration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Fuerza objetivo equivalente cl\u00ednica (dosis humana m\u00e1xima aprobada)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose arm, exploratory protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>30 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de varias semanas con un solo vial, menor volumen de reconstituci\u00f3n<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>40 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended-cycle studies, lower per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Multi-month protocols, comparative dose-response studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>60 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-dose comparative arm<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>80 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, low per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>100 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estudios multicohorte, protocolos de varios meses<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>120 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Maximum Bulk packs vial, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All eleven strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful for users minimising injection volume or running extended multi-month protocols from a single vial. Because reconstituted solution is stable for ~30 days, the optimal vial size for a given protocol depends on weekly dose \u00d7 weeks-per-vial trade-off. <\/p>\n<h2>Comparativa \u2014 Tirzepatida vs Semaglutida vs Retatrutida<\/h2>\n<p>Tirzepatide sits at the centre of the modern incretin-agonist studies landscape, between the single-receptor <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> (solo GLP-1) y el triple receptor <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> (GLP-1 + GIP + glucagon). Each step up the receptor ladder produces a progressively larger body-weight effect in head-to-head studies but also broader systemic signalling. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutida<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tirzepatida<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutida<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (simple)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP (doble)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + glucag\u00f3n (triple)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estructura pept\u00eddica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 (31 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GIP (39 aa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Similar a GIP (39 aa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~165 horas (~7 d\u00edas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~120 horas (~5 d\u00edas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 d\u00edas<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Anclaje de \u00e1cidos grasos<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Di\u00e1cido C18 + AEEA-AEEA<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Di\u00e1cido C20 + \u03b3Glu-\u03b3Glu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Di\u00e1cido C20 + \u03b3Glu<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Referencia de marca<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mounjaro \/ Zepbound<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">En investigaci\u00f3n (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,25\u20132,4 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2,5\u201315 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312 mg<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efecto en el peso corporal en ensayos<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15% (STEP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~22% (SURMOUNT-1)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24% (Fase 2)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Control gluc\u00e9mico, cardiovascular<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Combinaci\u00f3n gluc\u00e9mica + peso corporal, MASH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mayor efecto sobre el peso corporal<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The head-to-head SURPASS-2 trial (Frias et al., NEJM 2021) showed superior HbA1c and body-weight reduction with tirzepatide 15\u00a0mg vs semaglutide 1\u00a0mg over 40 weeks \u2014 one of the largest direct comparison datasets in incretin studies. For methodological detail on the dual- vs triple-agonist landscape, read <a href=\"https:\/\/medsbase.com\/es\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida: agonista triple vs dual<\/a> y <a href=\"https:\/\/medsbase.com\/es\/ozempic-vs-mounjaro\/\">Ozempic vs Mounjaro<\/a>. Users selecting between these peptides typically weigh receptor selectivity (cleaner pharmacology with semaglutide), magnitude of effect (greater with tirzepatide and retatrutide), and the strength of available trial data (extensive for semaglutide and tirzepatide, still maturing for retatrutide). <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> almacene los viales liofilizados refrigerados a 2\u20138 \u00b0C en su envase original para existencias de trabajo a corto plazo. Para almacenamiento a largo plazo sin abrir, congele a \u221220 \u00b0C. La tirzepatida liofilizada es estable bajo refrigeraci\u00f3n hasta 24 meses y a \u221220 \u00b0C hasta 36 meses. Evite ciclos de congelaci\u00f3n-descongelaci\u00f3n en el polvo liofilizado. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inyecte agua bacteriost\u00e1tica por la pared lateral del vial de p\u00e9ptido (no directamente sobre el polvo liofilizado). Para un vial de 10 mg, 2,0 mL de agua bacteriost\u00e1tica producen una concentraci\u00f3n de trabajo de 5 mg\/mL: 10 marcas en una jeringa de insulina U-100 equivalen a 500 mcg. Agite suavemente, no <strong>ajuste<\/strong> shake \u2014 and allow 2\u20135 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration. Because tirzepatide is dosed once weekly in protocols, a single reconstituted 10\u00a0mg vial typically supports 2\u20134 weeks of dosing depending on target dose; a 50\u00a0mg vial supports 10\u201320 weeks at clinical-equivalent doses. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is Tirzepatide used for in studies?<\/h3>\n<p>Tirzepatide is used in studies investigating glycaemic control, insulin sensitivity, body weight and adiposity, MASLD\/MASH liver disease, cardiovascular endpoints, sleep apnoea, and diabetic nephropathy. It is the most extensively characterised dual GLP-1\/GIP agonist and is the standard comparator arm for newer multi-agonist peptide studies. The pharmaceutical-grade tirzepatide sold here is <strong>ajuste<\/strong> FDA-approved for human therapeutic use and is supplied strictly for clinical studies. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia Tirzepatida de Semaglutida?<\/h3>\n<p>La diferencia estructural radica en el perfil de receptores y la estructura del p\u00e9ptido. Tirzepatida se basa en la estructura de 39 amino\u00e1cidos de GIP y coactiva tanto los receptores de GIP como de GLP-1. Semaglutida se basa en la estructura de 31 amino\u00e1cidos de GLP-1 y activa solo el receptor de GLP-1. El componente GIP en tirzepatida a\u00f1ade lip\u00f3lisis en tejido adiposo y aumentos modestos en el gasto energ\u00e9tico que los p\u00e9ptidos exclusivos de GLP-1 no producen. En ensayos comparativos directos (SURPASS-2), tirzepatida 15 mg produjo una reducci\u00f3n superior de HbA1c y peso corporal frente a semaglutida 1 mg durante 40 semanas. <\/p>\n<h3>\u00bfEn qu\u00e9 se diferencia Tirzepatida de Retatrutida?<\/h3>\n<p>Ambas se basan en estructuras de GIP, pero retatrutida a\u00f1ade actividad del receptor de glucag\u00f3n adem\u00e1s de GLP-1 y GIP, convirti\u00e9ndola en un agonista triple. El componente adicional de glucag\u00f3n contribuye a\u00fan m\u00e1s al gasto energ\u00e9tico y la lip\u00f3lisis de adipocitos. Los datos publicados de Fase 2 de retatrutida muestran una reducci\u00f3n de peso corporal de ~24% a 12 mg semanales, superando modestamente el 22% de tirzepatida en SURMOUNT-1. Tirzepatida cuenta con datos de ensayos m\u00e1s maduros; retatrutida a\u00fan se encuentra en desarrollo avanzado. <\/p>\n<h3>What is the typical Tirzepatide dose?<\/h3>\n<p>Los protocolos publicados suelen utilizar un esquema de titulaci\u00f3n que comienza con 2,5 mg semanales y aumenta en 2,5 mg cada 4 semanas hasta una dosis de mantenimiento de 5-15 mg semanales. Un vial de 10 mg reconstituido con 2,0 mL de agua bacteriost\u00e1tica produce 5 mg\/mL: 10 marcas en una jeringa U-100 equivalen a 500 mcg. <\/p>\n<h3>\u00bfEst\u00e1 Tirzepatida aprobada por la FDA?<\/h3>\n<p>Pharmaceutical tirzepatide is FDA-approved under the brand names Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023), manufactured to GMP standards by Eli Lilly. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar el Tirzepatida?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para existencias de trabajo a corto plazo, o \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar dentro de los 30 d\u00edas. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido. Proteja de la luz directa en todo momento. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo el Tirzepatida?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no sobre el polvo liofilizado), agite suavemente y permita de 2 a 5 minutos para la disoluci\u00f3n completa. No <strong>ajuste<\/strong> agite el vial. Una soluci\u00f3n correctamente reconstituida es transparente e incolora. Para un vial de 10 mg + 2.0 mL de diluyente, la concentraci\u00f3n de trabajo es de 5 mg\/mL. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries Tirzepatide in eleven lyophilized vial strengths: 5\u00a0mg, 10\u00a0mg, 15\u00a0mg, 20\u00a0mg, 30\u00a0mg, 40\u00a0mg, 50\u00a0mg, 60\u00a0mg, 80\u00a0mg, 100\u00a0mg, and 120\u00a0mg. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media del Tirzepatida?<\/h3>\n<p>El Tirzepatida tiene una vida media plasm\u00e1tica de aproximadamente 120 horas (~5 d\u00edas) tras la administraci\u00f3n subcut\u00e1nea. Esta vida media se logra mediante la uni\u00f3n reversible a la alb\u00famina s\u00e9rica circulante a trav\u00e9s del enlace de \u00e1cido di\u00e1cido graso C20 en la lisina 20, que protege al p\u00e9ptido de la eliminaci\u00f3n renal. Combinado con la doble sustituci\u00f3n de Aib (posiciones 2 y 13) que bloquea la escisi\u00f3n por DPP-4, esto permite un r\u00e9gimen de dosificaci\u00f3n semanal comparable a la vida media de ~165 horas del semaglutida. <\/p>\n<h3>\u00bfPor qu\u00e9 el Tirzepatida produce mayor p\u00e9rdida de peso que el Semaglutida?<\/h3>\n<p>The most-cited mechanism is the GIP-receptor component. GIP-receptor activation contributes additional effects that GLP-1 alone doesn&#8217;t produce: enhanced adipocyte lipolysis under fasting conditions, modest increases in resting energy expenditure, and CNS effects in the dorsomedial hypothalamus distinct from arcuate-nucleus GLP-1 signalling. The combined dual signal produces an additive body-weight reduction beyond GLP-1 alone in head-to-head study models. <\/p>\n<h3>Does Tirzepatide cause side reported effects?<\/h3>\n<p>El hallazgo m\u00e1s consistente es gastrointestinal: n\u00e1useas, supresi\u00f3n transitoria del apetito y retraso en el vaciado g\u00e1strico son dependientes de la dosis y tienden a atenuarse tras 4-8 semanas de dosificaci\u00f3n continua a medida que se desarrolla taquifilaxia del receptor. Hallazgos menos comunes incluyen efectos sobre la motilidad de la ves\u00edcula biliar y (en modelos de roedores con sensibilidad de c\u00e9lulas C tiroideas) hiperplasia de c\u00e9lulas C, siendo este \u00faltimo una se\u00f1al espec\u00edfica de especie que no se ha observado en humanos en seguimientos cl\u00ednicos a largo plazo. <\/p>\n<h3>Can Tirzepatide and Semaglutide be compared in studies?<\/h3>\n<p>S\u00ed: la comparaci\u00f3n directa es una de las preguntas m\u00e1s estudiadas en farmacolog\u00eda de incretinas. El ensayo cl\u00ednico SURPASS-2 compar\u00f3 directamente tirzepatida 15 mg frente a semaglutida 1 mg en pacientes con diabetes tipo 2; la evidencia precl\u00ednica y creciente evidencia del mundo real contin\u00faan extendiendo la comparaci\u00f3n a peso corporal, MASH y puntos finales cardiovasculares. El semaglutida sigue siendo el comparador est\u00e1ndar de GLP-1; el tirzepatida es el comparador est\u00e1ndar de agonista dual. <\/p>\n<h3>How long does Tirzepatide take to show effects in preclinical studies?<\/h3>\n<p>Acute pharmacodynamic effects on glucose tolerance and gastric emptying are detectable within hours of the first dose. Body-weight effects in DIO rodent models typically become statistically significant after 1\u20132 weeks of weekly dosing and continue to accrue through 8\u201316 weeks. Maximum effect on body composition is typically observed after 16\u201324 weeks of continuous dosing in study models, mirroring the human-trial trajectory. <\/p>\n<h3>\u00bfPuedo pedir Tirzepatida para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda Tirzepatida a todo el mundo desde nuestra red dedicada de env\u00edo de p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo independiente de p\u00e9ptidos. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/semaglutide\/\"><strong>Semaglutida<\/strong><\/a> \u2014 Single GLP-1 agonist (Ozempic\/Wegovy\/Rybelsus active) \u2014 standard glycaemic and CV-studies comparator<\/li>\n<li><a href=\"\/es\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 next-generation multi-axis metabolic support<\/li>\n<li><a href=\"\/es\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose tissue studies<\/li>\n<li><a href=\"\/es\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrially-encoded exercise-mimetic peptide \u2014 AMPK and insulin sensitivity<\/li>\n<li><a href=\"\/es\/cjc-1295-with-dac\/\"><strong>CJC-1295 con DAC<\/strong><\/a> \u2014 Long-acting GHRH analog for growth-axis studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Comparativa del panorama de incretinas de acci\u00f3n prolongada<\/strong><\/p>\n<p style=\"margin: 0;\">Consulte nuestras gu\u00edas comparativas: <a href=\"https:\/\/medsbase.com\/es\/retatrutide-vs-tirzepatide\/\"><strong>Retatrutide vs Tirzepatide \u2014 triple agonista vs dual agonista<\/strong><\/a> y <a href=\"https:\/\/medsbase.com\/es\/ozempic-vs-mounjaro\/\"><strong>Ozempic vs Mounjaro<\/strong><\/a>. Abarca farmacolog\u00eda de receptores, ingenier\u00eda de secuencias, vida media, respuesta a dosis, y los datos de ensayos comparativos que diferencian a tirzepatide de semaglutide (SURPASS-2) y de los resultados en Fase 2 del triple agonista retatrutide.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Agonista dual de los receptores GLP-1 + GIP<br \/>\n\u2705 Mayor efecto sobre el peso corporal de un solo p\u00e9ptido<br \/>\n\u2705 Supports glycaemic control<br \/>\n\u2705 Lip\u00f3lisis de adipocitos y gasto energ\u00e9tico<br \/>\n\u2705 Protocolos de dosificaci\u00f3n semanal<\/p>\n<p><strong>Tirzepatida<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70986,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,5418],"class_list":["post-70674","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-tirzepatide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70674"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70986"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70674"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70674"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70674"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}